Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder.
As previously announced, Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.